BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sardh E, Harper P. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria. J Intern Med 2022;291:593-610. [PMID: 35067977 DOI: 10.1111/joim.13443] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Lissing M, Vassiliou D, Floderus Y, Harper P, Yan J, Hagström H, Sardh E, Wahlin S. Risk for incident comorbidities, nonhepatic cancer and mortality in acute hepatic porphyria: A matched cohort study in 1244 individuals. J Inherit Metab Dis 2023;46:286-99. [PMID: 36546345 DOI: 10.1002/jimd.12583] [Reference Citation Analysis]
2 Ramzan A, Cao JJL, Frazer JS, Stein P, Ahmad S. A Case of Acute Intermittent Porphyria Leading to Severe Disability in a Young 21-Year-Old Female. Cureus 2023;15:e34757. [PMID: 36909084 DOI: 10.7759/cureus.34757] [Reference Citation Analysis]
3 Traber GM, Yu AM. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies. J Pharmacol Exp Ther 2023;384:133-54. [PMID: 35680378 DOI: 10.1124/jpet.122.001234] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
4 Storjord E, Airila-Månsson S, Karlsen K, Madsen M, Dahl JA, Landsem A, Fure H, Ludviksen JK, Fjøse JØ, Dickey AK, Karlsen BO, Waage Nielsen E, Mollnes TE, Brekke OL. Dental and Periodontal Health in Acute Intermittent Porphyria. Life (Basel) 2022;12. [PMID: 36013449 DOI: 10.3390/life12081270] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Scollan ME, Lauren CT. Photodermatoses: what's new. Curr Opin Pediatr 2022;34:374-80. [PMID: 35836395 DOI: 10.1097/MOP.0000000000001155] [Reference Citation Analysis]